Arbutus Biopharma Corporation beat EPS estimates 100% of the time across 1 reported quarters (1 beats, 0 misses). Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result |
|---|---|---|---|---|
| Q22026 FY2026 | — | — | — | Miss |
| Q12026 FY2026 | $-0.03 | $0.87 | +3000.0% | Beat |
Back to ABUS overview · ABUS holders · ABUS KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.